Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous cytokine-induced killer cell therapy for relapse prevention in high-risk diffuse large B-cell lymphoma
KCT0012770Phase 2Not yet recruiting
- Sponsor
- Ministry of Health & Welfare
- Start
- Nov 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous cytokine-induced killer cell therapy in diffuse large B-cell lymphoma (DLBCL), sponsored by Ministry of Health & Welfare. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
autologous cytokine-induced killer cell therapy
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0012770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012770.